Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Visudyne
Verteporfin is a photosensitizing agent used in photodynamic therapy (PDT) to treat certain eye conditions. It belongs to the class of benzoporphyrin derivatives and works by selectively damaging abnormal blood vessels in the eye when activated by light of a specific wavelength. This helps to slow or stop the leakage and growth of these vessels, preserving vision.
For the treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia, and ocular histoplasmosis.
Outcome:
Increased photosensitivity
Mechanism:
Additive photosensitizing effect
Outcome:
Potential for increased photosensitivity
Mechanism:
Unknown
Outcome:
No clinically significant interaction expected
Mechanism:
Different mechanisms of action
Most likely new formulation: Sustained-release intravitreal implant (Year: 2028, 30% confidence)
Based on current usage trends and clinical trial data, there is a low ( <5%) likelihood of any major regulatory changes to Verteporfin's approved indications in the next 2 years.
Photosensitizing Agent
Benzoporphyrin Derivative